GSK is currently the market leader in the meningococcal vaccine market, racking up sales of £1.26 billion (almost $1.6 billion) last year across the Bexsero and Menveo brands, but is having to ...

The concomitant administration of multiple vaccines at a single ... post-vac Intergroup difference –5% Meningococcal hSBA titer ≥4 % of subjects with hSBA ≥1:8 or with seroresponse ...

In February 2010, a quadrivalent conjugate vaccine (Menveo ... The proportions of subjects with hSBA titres ≥1:8 for the four meningococcal serogroups A, C, Y and W-135 were non-inferior ...

Hundreds have already taken advantage of the CLP’s free meningococcal B vaccination program, which provides protection for infants aged six weeks to two years, and teens aged 14 to 19 years.

Background: Given the broad age range across which the quadrivalent meningococcal ... vaccines did not reduce immune responses to diphtheria, tetanus, poliovirus, hepatitis B, Haemophilus ...